Author

Orlov A

professor, Uppsala University - Cited by 10,792 - radiopharmaceuticals

Biography

Orlov A is currently working as a Professor in the Department of Medicine. His research interests includes Medicine. He is serving as an editorial member and reviewer of several international reputed journals. He has successfully completed his Administrative responsibilities. He has authored of many research articles/books related to Medicine.
Title
Cited by
Year
Phase I trial of 99mTc-(HE) 3-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer
O Bragina, V Chernov, A Schulga, E Konovalova, E Garbukov, ...Journal of Nuclear Medicine 63 (4), 528-535, 2022202
33
2022
JAK‐STAT core cancer pathway: An integrative cancer interactome analysis
F Erdogan, TB Radu, A Orlova, AK Qadree, ED de Araujo, J Israelian, ...Journal of cellular and molecular medicine 26 (7), 2049-2062, 2022202
15
2022
HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers
SS Rinne, CD Leitao, A Abouzayed, A Vorobyeva, V Tolmachev, S Ståhl, ...Cancers 13 (19), 491, 2021202
7
2021
Targeting HER2 expressing tumors with a potent drug conjugate based on an albumin binding domain-derived affinity protein
J Garousi, H Ding, E von Witting, T Xu, A Vorobyeva, M Oroujeni, A Orlova, ...Pharmaceutics 13 (11), 1847, 2021202
6
2021
Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T‐cell lymphoma
H Sorger, S Dey, PA Vieyra‐Garcia, D Pölöske, AR Teufelberger, ...EMBO Molecular Medicine 14 (12), e15200, 2022202
6
2022
Affibody-mediated PNA-based pretargeted cotreatment improves survival of trastuzumab-treated mice bearing HER2-expressing xenografts
M Oroujeni, H Tano, A Vorobyeva, Y Liu, O Vorontsova, T Xu, ...Journal of Nuclear Medicine 3 (7), 104-1051, 2022202
6
2022
The influence of domain permutations of an albumin-binding domain-fused her2-targeting affibody-based drug conjugate on tumor cell proliferation and therapy efficacy
W Yin, T Xu, M Altai, M Oroujeni, J Zhang, A Vorobyeva, O Vorontsova, ...Pharmaceutics 13 (11), 1974, 2021202
5
2021
Novel polyetherimides based on 5-Methyl-1, 3-phenylene-bis-4-oxyphthalic acid dianhydride: synthesis and physicochemical properties
Novel polyetherimides based on 5-Methyl-1, 3-phenylene-bis--oxyphthalic acid dianhydride: synthesis and physicochemical propertiesAM Orlova, AY Tsegelskaya, TI Kolesnikov, IG Abramov, AA KuznetsovPolymer Science, Series B, 1-9, 2022202
4
2022
Structural and mutational analysis of member-specific STAT functions
F Erdogan, AK Qadree, TB Radu, A Orlova, ED de Araujo, J Israelian, ...Biochimica et Biophysica Acta (BBA)-General Subjects 1866 (3), 130058, 2022202
4
2022
Design, synthesis, and evaluation of linker-optimised PSMA-targeting radioligands
F Lundmark, G Olanders, SS Rinne, A Abouzayed, A Orlova, ...Pharmaceutics 14 (5), 1098, 2022202
3
2022
Effect of Uniform Deformation on the Mechanical and Gas Transport Characteristics of Polyimides Based on Diethyltoluylenediamine
AY Alentiev, SV Chirkov, RY Nikiforov, NA Belov, AM Orlova, ...Membranes and Membrane Technologies 4 (2), 9-100, 2022202
3
2022
Effect of Supercritical CO2 Treatment on Mechanical and Gas Transport Characteristics of Polyimides Based on Diethyl Toluene Diamine Isomers
AY Alentiev, SV Chirkov, RY Nikiforov, NA Belov, AM Orlova, ...Membranes and Membrane Technologies 4 (), 162-169, 2022202
3
2022
Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of …
Phase I Trial of [99mTc]Tc-maSSS-PEG-RM6, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of …V Chernov, A Rybina, R Zelchan, A Medvedeva, O Bragina, N Lushnikova, ...Cancers 15 (6), 1631, 030
2
2023
Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071
Experimental Therapy of HER-Expressing Xenografts Using the Second-Generation HER-Targeting Affibody Molecule 188Re-ZHER:41071Y Liu, A Vorobyeva, A Orlova, MW Konijnenberg, T Xu, O Bragina, ...Pharmaceutics 14 (5), 109, 0
2
2022
Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant …
Y Liu, S Yu, T Xu, V Bodenko, A Orlova, M Oroujeni, SS Rinne, ...Pharmaceutics 14 (7), 1475, 0
2
2022
Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3
M Oroujeni, EA Bezverkhniaia, T Xu, Y Liu, EV Plotnikov, I Karlberg, ...Pharmaceutics 14 (9), 1780, 0
2
2022
The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer
M Li, R Zelchan, A OrlovaBiomedicines 10 (10), 533, 0
2
2022
Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response …
Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER Expression and Monitoring of Early Response …V Tolmachev, V Bodenko, M Oroujeni, S Deyev, E Konovalova, A Schulga, ...International Journal of Molecular Sciences 3 (3), 15181, 0
2
2022
Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules
SS Rinne, W Yin, AM Borras, A Abouzayed, CD Leitao, A Vorobyeva, ...Biomedicines 0 (6), 293, 2022202
1
2022
Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2
T Xu, J Zhang, M Oroujeni, MS Tretyakova, V Bodenko, MV Belousov, ...Pharmaceutics 4 (3), 522, 2022202
1
2022

Referred From: https://scholar.google.com/citations?hl=en&user=Xvh-P-cAAAAJ

Cited by
Citations 10792
h-index 58
i10-index 197
Recommended Journals
Open Access Journals